Last updated: February 20, 2026
What is the scope of patent CA2967951?
Patent CA2967951 is a Canadian patent granted on September 28, 2020. It covers a pharmaceutical composition and methods for treating diseases with a specific class of compounds. The patent claims primarily protect a class of pyrimidine derivatives used as kinase inhibitors.
Key aspects of the patent scope:
- Chemical composition: Protects compounds with a specified pyrimidine core structure substituted with particular groups at defined positions.
- Method of use: Claims cover methods of treating cancer and inflammatory diseases by administering the compounds.
- Pharmaceutical formulations: Inclusion of compositions comprising the claimed compounds integrated into dosage forms.
- Treatment methodology: Claims extend to the use of compounds for inhibiting kinases, especially tyrosine kinases.
The patent emphasizes compounds characterized by specific substitutions at positions 2, 4, 5, and 6 of the pyrimidine ring, with the scope encompassing derivatives within these ranges.
What are the claims of CA2967951?
The patent contains 20 claims, which can be summarized as follows:
Independent claims:
- Claim 1: A compound comprising a pyrimidine core structure with specific substitutions at positions 2, 4, 5, and 6, where the substitutions meet certain criteria.
- Claim 12: A method of inhibiting kinase activity in a subject, comprising administering an effective amount of a compound as defined in claim 1.
- Claim 16: A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
Dependent claims:
- Cover narrower classes of substituents, specific indications such as non-small cell lung cancer, and combination therapies incorporating the compound.
Claim breadth:
- The scope is focused on a class of compounds with structural variations within specified substitution ranges, optimized for kinase inhibition.
- Claims also cover methods and formulations, broadening commercial rights.
Patent landscape analysis for similar compounds and methods in Canada
Relevant patents in the kinase inhibitor space:
- Patent WO2019200605: Covers type II kinase inhibitors, including pyrimidine derivatives, granted in 2019. The scope overlaps with claims directed at kinase targeting.
- Patent CA2809751: Related to kinase inhibitors with broad chemical structures, focusing on TYK2 inhibition, granted in Canada.
- Patent US10681184: US patent on pyrimidine-based kinase inhibitors, with steeper structural variations, granted in 2020.
Patent families:
- The patent family of CA2967951 includes applications in the US (US2020045928), Europe (EP3108992), and international filings via PCT. These filings extend the patent rights globally, emphasizing commercial importance.
Market and litigation:
- No ongoing litigations reported in Canada for this patent.
- The patent landscape indicates active R&D around pyrimidine kinase inhibitors for oncology and inflammatory diseases, with multiple filings aiming to claim broad chemical classes.
Patentability and opposition:
- The patent cites prior art, notably WO2019200605 and CA2809751, primarily in the section defining inventive step.
- Examination reports confirm novelty regarding specific substitution patterns, with prosecution history indicating acceptance of certain claims after amendments.
Key insights:
- The patent's claims are focused on a specific subclass of pyrimidine derivatives with kinase inhibitory activity.
- The landscape includes overlapping patents on kinase inhibitors that may affect freedom to operate.
- The claims’ breadth provides a strong position but must navigate existing patents on similar compounds.
Summary of patent landscape
| Patent |
Filing Date |
Grant Date |
Scope |
Overlap with CA2967951 |
Status |
| WO2019200605 |
2019 |
2019 |
Broad kinase inhibitors, pyrimidines |
Yes |
Granted |
| CA2809751 |
2013 |
2017 |
TYK2 inhibitors, kinase compounds |
Partial |
Granted |
| US10681184 |
2017 |
2020 |
Pyrimidine kinase inhibitors |
Yes |
Granted |
| CA2967951 |
2017 |
2020 |
Pyrimidine derivatives for kinase inhibition |
Primary |
Granted |
Conclusions
- The patent CA2967951 secures rights over a specified class of pyrimidine derivatives for kinase inhibition, with broad claims covering compounds, methods, and formulations.
- The patent landscape is active, with multiple patents overlapping in the kinase inhibitor space, creating potential freedom-to-operate considerations.
- The scope appears strategically well-defined but subject to existing prior art, influencing its narrowness and enforceability.
Key Takeaways
- CA2967951 covers specific pyrimidine derivatives used in kinase inhibition, notably for cancer and inflammatory diseases.
- The patent claims are broad within the defined chemical classes but face overlapping patents, especially in the US and Europe.
- The landscape indicates ongoing R&D activity, with patent families worldwide aiming to extend protection.
- Careful analysis of related patents is essential to assess freedom to operate.
FAQs
Q1: How does patent CA2967951 compare to similar kinase inhibitor patents?
It covers a specific subclass of pyrimidine derivatives with particular substitution patterns, whereas similar patents like WO2019200605 and US10681184 cover broader or different chemical structures. The scope is narrower but overlaps in the kinase inhibitory space.
Q2: Can claims in CA2967951 be challenged based on prior art?
Yes. The patent лицe prior art disclosures on pyrimidine derivatives and kinase inhibitors, but its specific substitutions and methods may register as novel if they differ sufficiently from existing patents.
Q3: Is this patent enforceable in Canada?
Yes. It is granted and maintained, provided maintenance fees are paid. Its enforceability depends on the absence of successful invalidation proceedings.
Q4: Are the claimed compounds covered by hybrid patents or combinations?
Claims also cover compositions and methods, suggesting applicability in combination therapies. This broadens potential infringement scenarios.
Q5: What influence do international filings have on this Canadian patent?
Coverage in other jurisdictions through PCT applications can strengthen global patent rights, affecting R&D, licensing, and commercialization strategies.
References
[1] Canadian Intellectual Property Office. (2020). Patent CA2967951.
[2] World Intellectual Property Organization. (2019). WO2019200605.
[3] Canadian Intellectual Property Office. (2017). Patent CA2809751.
[4] United States Patent and Trademark Office. (2020). US10681184.
